News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biotech Support Group Release: Enhanced Betatrophin and Type 1 Diabetes Research Via Sample Preparation Reagent AlbuVoid™


10/7/2013 8:21:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PRLog (Press Release) - Oct. 6, 2013 - MONMOUTH JUNCTION, N.J. -- MONMOUTH JUNCTION, N.J. -- Authors Espes et al published an article in the journal Diabetologia which discovered an increase in hormone betatrophin in type 1 diabetics as compared to health individuals. Betatrophin causes an increase of pancreatic ß cell replication and regulates glucose levels. Found in liver and adipose tissue, the hormone also increases ß cell mass expansion. Analysis of betatrophin by mass spectrometry (MS) or gel electrophoresis could require enriching the protein mixture and depleting high abundance proteins to display less abundant proteins. The article titled, “Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes” utilized AlbuVoid™’s albumin depletion protocol for removing albumin from plasma samples. The article quotes AlbuVoid™ from Biotech Support Group, “Plasma samples were depleted of albumin using AlbuVoid Albumin Depletion Kit (Biotech Support Group, Monmouth Junction, NJ, USA). Data were normalized for total protein content.” Betatrophin increases proliferation of beta cell and this study identified double the concentration of betatrophin as measured by western immunoblot using a betatrophin primary antibody in type 1 diabetics. Moreover factors such as age in healthy controls displayed a direct relationship with increase in betatrophin whereas triacylglycerol, LDL-cholesterol, HDL-cholesterol levels and insulin were not affected. Increasing concentrations of betatrophin did not prevent against the loss of C-peptide suggesting type 1 diabetes on betatropin treatment would benefit from combination treatment. The authors concluded, “An intervention in patients with type 1 diabetes with betatrophin treatment might require supraphysiological dosing as well as combination with immune regulatory treatment.”

For detailed protocols of the published article click

http://link.springer.com/article/10.1007/s00125-013-3071-...

Characteristics of AlbuVoid™

Albumin voids in flow-through >95%, with <30 minute bind/wash/elute protocol

Low abundance enrichment equivalent or better than hexa-peptides or antibodies

Disposable, cost-effective, no column regeneration or cross-contamination

Mild elution maintains tertiary structure and simple transfer to secondary analysis

The eluted fractions retain their enzymatic and biological activity

Removes albumin from many species including human, mouse, sheep, bovine, goat, rat, calf, cell culture.

The eluted fraction is compatible with LC-MS, activity based protein profiling and proteomic studies.

About Biotech Support Group LLC

Biotech Support Group LLC is a leading developer of proteomic and genomic sample preparation and enrichment products. It’s principal products include: AlbuVoid™ for albumin depletion, Cleanascite™ for lipid adsorption and clarification, HemogloBind™ & HemoVoid™ for hemoglobin removal, NuGel™ for functional & chemical proteomics, and ProCipitate™ & ProPrep™ for nucleic acid isolation. For more information, go to http://www.biotechsupportgroup.com

Contact:

Dr. Swapan Roy

Biotech Support Group

732-274-2866

sales@biotechsupportgroup.com

http://www.biotechsupportgroup.com

Reference

Espes, Daniel, Joey Lau, and Per-Ola Carlsson. "Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes." Diabetologia(2013): 1-4.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES